Zacks upgraded shares of Vanda Pharmaceuticals (NASDAQ:VNDA) from a neutral rating to an outperform rating in a report released on Tuesday, AnalystRatingsNetwork.com reports. Zacks currently has $7.10 price objective on the stock.
Shares of Vanda Pharmaceuticals (NASDAQ:VNDA) traded up 2.26% during mid-day trading on Tuesday, hitting $13.60. The stock had a trading volume of 5,665,852 shares. Vanda Pharmaceuticals has a 1-year low of $2.92 and a 1-year high of $13.49. The stock’s 50-day moving average is $9.17 and its 200-day moving average is $9.34. The company’s market cap is $387.4 million. Vanda Pharmaceuticals also was the recipient of some unusual options trading activity on Monday. Stock traders purchased 15,290 call options on the stock. This represents an increase of 144% compared to the average daily volume of 6,273 call options.
Vanda Pharmaceuticals (NASDAQ:VNDA) last released its earnings data on Thursday, November 7th. The company reported ($0.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by $0.13. The company had revenue of $8.70 million for the quarter, compared to the consensus estimate of $8.45 million. During the same quarter in the prior year, the company posted ($0.19) earnings per share. The company’s quarterly revenue was up 4.8% on a year-over-year basis. Analysts expect that Vanda Pharmaceuticals will post $-0.61 EPS for the current fiscal year.
Separately, analysts at Lazard Capital Markets reiterated a buy rating on shares of Vanda Pharmaceuticals in a research note to investors on Monday, October 21st. They now have a $22.00 price target on the stock. Five investment analysts have rated the stock with a buy rating, The stock has a consensus rating of Buy and an average price target of $14.68.
Vanda Pharmaceuticals Inc (NASDAQ:VNDA) is a biopharmaceutical company.
To view Zacks’ full report, visit www.zacks.com
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.